Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
“We remain dedicated to advancing the field of research and treatment for this disease in order to better (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Clayton
- Anavex to Present at Sigma-1 Receptors Symposium
The Physiopathology of Sigma-1 Receptors symposium is being hosted by the Nice Sophia Antipolis University (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Life Sciences Announces Achievement of Enrollment Target for ANAVEX®2-73 Phase 2 PDD Trial
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media
- Anavex Life Sciences Appoints Distinguished Researcher to Scientific Advisory Board
Chief of the Division of Clinical Neurophysiology and Epilepsy and Professor of Neurology at Harvard Medical He graduated from Dartmouth College Magna Cum Laude and Dartmouth Medical School. Director of the Massachusetts General Hospital Epilepsy Service and Professor of Neurology at Harvard Medical projected in any of such statements due to various factors, including the risks set forth in the Company’s most Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com Social Media: Bill Douglass Gotham
- Anavex Life Sciences Strengthens Management Team and Board of Directors
Management Accounting, Internal Audit and Risk Management at Stroeer SE & Co KGaA, a publicly listed $3bn media (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Clayton
- Anavex to Present at 27th Annual ROTH Conference on March 11th
Hosted by ROTH Capital Partners, the invitation-only event is one of the largest investor conferences (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Life Sciences Presents ANAVEX®2-73 Data at 12th Clinical Trials on CTAD 2019 Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Email
- Anavex Life Sciences Receives Approval from Health Canada & UK MHRA Expanding Phase 2b/3 ANAVEX®2-73
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:
- U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: 866-505-2895 Email: ir@anavex.com Media
- Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most
